Should the Denosumab Metastasis Prevention Trial Change Practice for Men with Nonmetastatic Prostate Cancer?

由 Saylor, Philip J., Michaelson, M. Dror
出版 2012

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

由 Gao, Xin, McDermott, David F., Michaelson, M. Dror
發表在 Oncologist (2019)

Prostate cancer (metastatic)

由 Michaelson, M Dror, Smith, Matthew R R, Talcott, James A A
出版 2003

Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer

由 Saylor, Philip J., Kaufman, Donald S., Michaelson, M. Dror, Lee, Richard J., Smith, Matthew R.
出版 2010

Treatment sequences for advanced renal cell carcinoma: A health economic assessment

由 Deniz, Baris, Ambavane, Apoorva, Yang, Shuo, Altincatal, Arman, Doan, Justin, Rao, Sumati, Michaelson, M. Dror
發表在 PLoS One (2019)

Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metast...

由 Saylor, Philip J., Mahmood, Umar, Kunawudhi, Anchisa, Smith, Matthew R., Palmer, Edwin L., Michaelson, M. Dror
出版 2012

Application of dynamic modeling for survival estimation in advanced renal cell carcinoma

由 Deniz, Baris, Altincatal, Arman, Ambavane, Apoorva, Rao, Sumati, Doan, Justin, Malcolm, Bill, Michaelson, M. Dror, Yang, Shuo
發表在 PLoS One (2018)

Management of Complications of Prostate Cancer Treatment

由 Michaelson, M. Dror, Cotter, Shane E., Gargollo, Patricio C., Zietman, Anthony L., Dahl, Douglas M., Smith, Matthew R.
出版 2008

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

由 Molina, Ana M., Hutson, Thomas E., Larkin, James, Gold, Anne M., Wood, Karen, Carter, Dave, Motzer, Robert, Michaelson, M. Dror
出版 2013

Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa

由 Cella, David, Cappelleri, Joseph C., Bushmakin, Andrew, Charbonneau, Claudie, Li, Jim Z., Kim, Sindy T., Chen, Isan, Michaelson, M. Dror, Motzer, Robert J.
出版 2009

Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer

由 Michaelson, M. Dror, Kaufman, Donald S., Lee, Hang, McGovern, Francis J., Kantoff, Philip W., Fallon, Mary Anne, Finkelstein, Joel S., Smith, Matthew R.
出版 2007

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

由 DePrimo, Samuel E, Bello, Carlo L, Smeraglia, John, Baum, Charles M, Spinella, Dominic, Rini, Brian I, Michaelson, M Dror, Motzer, Robert J
出版 2007

Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials

由 Tannir, Nizar M., Figlin, Robert A., Gore, Martin E., Michaelson, M. Dror, Motzer, Robert J., Porta, Camillo, Rini, Brian I., Hoang, Caroline, Lin, Xun, Escudier, Bernard
發表在 Clin Genitourin Cancer (2017)

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

由 Donskov, Frede, Michaelson, M Dror, Puzanov, Igor, Davis, Mellar P, Bjarnason, Georg A, Motzer, Robert J, Goldstein, David, Lin, Xun, Cohen, Darrel P, Wiltshire, Robin, Rini, Brian I
發表在 Br J Cancer (2015)

Radium-223 dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases

由 McKay, Rana R., Bossé, Dominick, Gray, Kathryn P., Michaelson, M. Dror, Krajewski, Katherine, Jacene, Heather A., Walsh, Meghara, Bellmunt, Joaquim, Pomerantz, Mark, Harshman, Lauren C., Choueiri, Toni K.
發表在 Clin Cancer Res (2018)

Two Phase II Trials of the Novel Akt Inhibitor Perifosine in Patients with Advanced Renal Cell Carcinoma Following Progression on VEGF-Targeted Therapy

由 Cho, Daniel C., Hutson, Thomas E., Samlowski, Wolfram, Sportelli, Peter, Somer, Brad, Richards, Paul, Sosman, Jeffrey A., Puzanov, Igor, Michaelson, M. Dror, Flaherty, Keith T., Figlin, Robert A, Vogelzang, Nicholas J
出版 2012

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma

由 Cella, David, Davis, Mellar P, Négrier, Sylvie, Figlin, Robert A, Michaelson, M Dror, Bushmakin, Andrew G, Cappelleri, Joseph C, Sandin, Rickard, Korytowsky, Beata, Charbonneau, Claudie, Matczak, Ewa, Motzer, Robert J
發表在 Cancer (2014)

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

由 Hudes, Gary R., Carducci, Michael A., Choueiri, Toni K., Esper, Peg, Jonasch, Eric, Kumar, Rashmi, Margolin, Kim A., Michaelson, M. Dror, Motzer, Robert J., Pili, Roberto, Roethke, Susan, Srinivas, Sandy
發表在 J Natl Compr Canc Netw (2011)

A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystecto...

由 Michaelson, M. Dror, Hu, Chen, Pham, Huong T., Dahl, Douglas M., Lee-Wu, Chin, Swanson, Gregory P., Vuky, Jacqueline, Lee, R. Jeffrey, Souhami, Luis, Chang, Brian, George, Asha, Sandler, Howard, Shipley, William
發表在 Int J Radiat Oncol Biol Phys (2016)

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases

由 Lee, Richard J., Saylor, Philip J., Michaelson, M. Dror, Rothenberg, S. Michael, Smas, Malgorzata E., Miyamoto, David T., Gurski, Carol A., Xie, Wanling, Maheswaran, Shyamala, Haber, Daniel A., Goldin, Jonathan G., Smith, Matthew R.
出版 2013